The SEC has announced the new rate for fees that public companies and other issuers pay to register their securities. The rate, for fiscal year 2018, is $124.50 per million dollars.
Joe Mont
Killing the SEC and other plans to redraft regulatory agencies
The Competitive Enterprise Institute has responded to a White House Executive Order with new proposals to redraft and refocus regulatory agencies. Eliminating the SEC and FDIC are among the not-so-modest proposals.
CMS considers trimming medical care rulebook
CMS, the agency that administers Medicare and other health insurance programs, is talking to medical professonals in an effort to reduce burdensome and unecessary rules, says Administrator Seema Verma.
EPA head urges cattlemen to denounce WOTUS rule, support repeal
EPA Administrator Scott Pruitt appears in a new video that urges the nation’s cattlemen to support and comment on a proposal to repeal the controversial Waters of the United States rule.
A dire warning from White House’s cyber-security advisers
The National Infrastructure Advisory Council, a cyber-security task force that advises the White House, says national cyber-security efforts are “falling short,” in a new report. It provides recommendations for both the public and private sectors.
Icahn bids adieu as Trump’s unofficial deregulation guru
Pressured by allegations of conflicts of interest, billionaire investor Carl Icahn has resigned from his role as a special advisor to President Donald Trump on deregulatory efforts.
OCC issues higher-loan-to-value lending guidance
The Office of the Comptroller of the Currency has released new guidance intended “to spur community revitalization” with the prudent and appropriate use of higher-loan-to-value lending.
Scam and money laundering puts former Wells Fargo manager in jail
A former Wells Frago bank manager is headed to jail for his role in a $1.66 million mass mailing scam that was facilitated with a money laundering scheme.
Medical device CEO convicted of $750 million securities fraud
A federal jury has convicted the former chief executive officer of a publicly traded medical device compan for his role in orchestrating a fraud scheme that led to $750 million in shareholder losses.
Mylan will pay $465 million to resolve False Claims Act liability
Mylan, maker of the EpiPen, has agreed to pay $465 million to settle Department of Justice allegations that it violated the False Claims Act by misclassifying the epinephrine injector as a generic drug to avoid paying Medicaid rebates.


